

Pheochromocytoma - Pipeline Insight, 2021

<https://marketpublishers.com/r/PA5726B1DD02EN.html>

Date: March 2021

Pages: 60

Price: US\$ 1,500.00 (Single User License)

ID: PA5726B1DD02EN

Abstracts

This report can be delivered to the clients within 24 Hours

DelveInsight's, "Pheochromocytoma - Pipeline Insight, 2021," report provides comprehensive insights about 8+ companies and 8+ pipeline drugs in Pheochromocytoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

Pheochromocytoma Understanding

Pheochromocytoma: Overview

Pheochromocytoma is a rare tumor that usually starts in the cells of one of your adrenal glands. It results in the release of too much epinephrine and norepinephrine, hormones that control heart rate, metabolism, and blood pressure. Pheochromocytoma may occur as a single tumor or as more than one growth. It usually develops in the center (medulla) of one or both adrenal glands. Symptoms associated with pheochromocytomas include high blood pressure (hypertension), headaches, excessive sweating, and/or heart palpitations. In approximately 25 to 35 percent of cases, pheochromocytomas may be inherited as an autosomal dominant trait. Blood and urine analysis can confirm a diagnosis of pheochromocytoma by detecting elevated levels of catecholamines or its metabolites in the urine and blood (plasma). Phenoxymethamine

or a similar drug is generally given to stop hormone action. The most common surgical procedure for treating pheochromocytoma is laparoscopic adrenalectomy. Radiation therapy, in which radiation is used to target and destroy cancer cells, and certain combinations of anticancer drugs (chemotherapy) may also be used to treat individuals with malignant pheochromocytoma.

'Pheochromocytoma - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Pheochromocytoma pipeline landscape is provided which includes the disease overview and Pheochromocytoma treatment guidelines. The assessment part of the report embraces, in depth Pheochromocytoma commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Pheochromocytoma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Pheochromocytoma R&D. The therapies under development are focused on novel approaches to treat/improve Pheochromocytoma.

Pheochromocytoma Emerging Drugs Chapters

This segment of the Pheochromocytoma report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Pheochromocytoma Emerging Drugs

Sunitinib: Pfizer

Sunitinib is a novel oral multitargeted tyrosine kinase inhibitor with antitumor and antiangiogenic activities. Sunitinib is approved in first-line treatment for patients with

advanced renal cell carcinoma (RCC) and for the treatment of patients with gastrointestinal stromal tumors (GIST) after disease progression or intolerance to imatinib mesylate therapy. The drug is in Phase II clinical studies for the treatment of Pheochromocytoma.

Guadecitabine: Astex Pharmaceuticals

Guadecitabine is a next-generation DNA hypomethylating agent. Guadecitabine is rationally designed to be resistant to degradation by cytidine deaminase, prolonging the exposure of tumor cells to the active metabolite, decitabine, thus ensuring greater uptake of decitabine into the DNA of rapidly dividing cancer cells. Guadecitabine-mediated inhibition of DNA methylation upregulates tumor-associated antigens and may sensitize tumor cells to other anticancer agents, including immunotherapeutics, as well as resensitize resistant cancer cells to chemotherapeutics. The drug is in Phase II clinical evaluation for the treatment of Pheochromocytoma.

Further product details are provided in the report.....

Pheochromocytoma: Therapeutic Assessment

This segment of the report provides insights about the different Pheochromocytoma drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Pheochromocytoma

There are approx. 8+ key companies which are developing the therapies for Pheochromocytoma. The companies which have their Pheochromocytoma drug candidates in the most advanced stage, i.e. Preregistration include, Pfizer.

Phases

DelveInsight's report covers around 8+ products under different phases of clinical development like

Late stage products (Phase III)

Mid-stage products (Phase II)

Early-stage product (Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Pheochromocytoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral

Parenteral

Intravitreal

Subretinal

Topical

Molecule Type

Products have been categorized under various Molecule types such as

Monoclonal Antibody

Peptides

Polymer

Small molecule

Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Pheochromocytoma: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Pheochromocytoma therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Pheochromocytoma drugs.

Pheochromocytoma Report Insights

Pheochromocytoma Pipeline Analysis

Therapeutic Assessment

Unmet Needs

Impact of Drugs

Pheochromocytoma Report Assessment

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

How many companies are developing Pheochromocytoma drugs?

How many Pheochromocytoma drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Pheochromocytoma?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Pheochromocytoma therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Pheochromocytoma and their status?

What are the key designations that have been granted to the emerging drugs?

Key Players

Pfizer

Exelixis

Ipsen

Genentech

Astex Pharmaceuticals

Advanced Accelerator Applications

Key Products

Sunitinib

Cabozantinib

Atezolizumab

Guadecitabine

Lutetium-177 oxodotreotide

Contents

Introduction

Executive Summary

Pheochromocytoma: Overview

- Causes
- Mechanism of Action
- Signs and Symptoms
- Diagnosis
- Disease Management

Pipeline Therapeutics

- Comparative Analysis

Therapeutic Assessment

- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type

Pheochromocytoma – DelveInsight's Analytical Perspective

In-depth Commercial Assessment

- Pheochromocytoma companies' collaborations, Licensing, Acquisition -Deal Value

Trends

Pheochromocytoma Collaboration Deals

- Company-Company Collaborations (Licensing / Partnering) Analysis
- Company-University Collaborations (Licensing / Partnering) Analysis

Late Stage Products (Preregistration)

- Comparative Analysis

Drug name: Company name

- Product Description
- Research and Development
- Product Development Activities

Drug profiles in the detailed report.....

Mid Stage Products (Phase II)

- Comparative Analysis

Sunitinib: Pfizer

- Product Description
- Research and Development
- Product Development Activities

Drug profiles in the detailed report.....

Early Stage Products (Phase I)

- Comparative Analysis

Drug name: Company name

- Product Description
- Research and Development
- Product Development Activities

Drug profiles in the detailed report.....

Preclinical and Discovery Stage Products

- Comparative Analysis

Drug name: Company name

- Product Description
- Research and Development
- Product Development Activities

Drug profiles in the detailed report.....

Inactive Products

- Comparative Analysis

Pheochromocytoma Key Companies

Pheochromocytoma Key Products

Pheochromocytoma- Unmet Needs

Pheochromocytoma- Market Drivers and Barriers

Pheochromocytoma- Future Perspectives and Conclusion

Pheochromocytoma Analyst Views

Pheochromocytoma Key Companies

Appendix

List Of Tables

LIST OF TABLES

Table 1 Total Products for Pheochromocytoma

Table 2 Late Stage Products

Table 3 Mid Stage Products

Table 4 Early Stage Products

Table 5 Pre-clinical & Discovery Stage Products

Table 6 Assessment by Product Type

Table 7 Assessment by Stage and Product Type

Table 8 Assessment by Route of Administration

Table 9 Assessment by Stage and Route of Administration

Table 10 Assessment by Molecule Type

Table 11 Assessment by Stage and Molecule Type

Table 12 Inactive Products

List Of Figures

LIST OF FIGURES

Figure 1 Total Products for Pheochromocytoma

Figure 2 Late Stage Products

Figure 3 Mid Stage Products

Figure 4 Early Stage Products

Figure 5 Preclinical and Discovery Stage Products

Figure 6 Assessment by Product Type

Figure 7 Assessment by Stage and Product Type

Figure 8 Assessment by Route of Administration

Figure 9 Assessment by Stage and Route of Administration

Figure 10 Assessment by Molecule Type

Figure 11 Assessment by Stage and Molecule Type

Figure 12 Inactive Products

I would like to order

Product name: Pheochromocytoma - Pipeline Insight, 2021

Product link: <https://marketpublishers.com/r/PA5726B1DD02EN.html>

Price: US\$ 1,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/PA5726B1DD02EN.html>